Welcome to our dedicated page for Ufp Technologies news (Ticker: UFPT), a resource for investors and traders seeking the latest updates and insights on Ufp Technologies stock.
UFP Technologies Inc. reports developments for a contract development and manufacturing organization focused on single-use and single-patient medical devices. Company news commonly covers quarterly and annual results, non-GAAP measures such as adjusted EBITDA and adjusted EPS, program ramps, backlog commentary, acquisition integration, and manufacturing capacity tied to medical-device customers.
Updates also include customer supply agreements, new program launches, investor conference participation, and governance matters such as executive succession planning. The company's products and components are used across medical device, wound care, infection prevention, minimally invasive surgery, wearable, orthopedic soft-goods, and orthopedic implant-packaging applications.
UFP Technologies (Nasdaq: UFPT) reported Q1 2026 net income of $17.5M and net sales of $154.2M, increases of 1.8% and 4.1% year-over-year. GAAP EPS was $2.24 and adjusted EPS was $2.48. Medical sales rose 5.9% while non-medical sales fell 15%.
Adjusted EBITDA was $31.0M. Company cited new Dominican Republic facilities in Q2 to expand capacity and noted start-up and labor inefficiency costs weighed on EPS growth.
UFP Technologies (Nasdaq: UFPT) will report first quarter 2026 financial results on Monday, May 4, 2026 after market close. A conference call to discuss results is scheduled for Tuesday, May 5, 2026 at 8:30 AM Eastern.
Dial-in numbers, a live webcast, and a replay will be available on the company’s Investor Relations website at https://ufpt.com/investors/.
UFP Technologies (Nasdaq: UFPT) announced that President Mitchell Rock and CFO Ron Lataille will participate in a virtual fireside chat and host 1x1 investor meetings at the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026, beginning at about 10:30 AM ET.
The company is presenting to investors and making management available for one-on-one meetings during the forum.
UFP Technologies (Nasdaq: UFPT) will present and host 1x1 investor meetings at the Raymond James 47th Annual Institutional Investors Conference in Orlando, March 1-4, 2026. Chairman & CEO R. Jeffrey Bailly and CFO Ron Lataille will present on March 3, 2026 at 2:50 PM ET. A live webcast of the presentation will be available.
UFP Technologies (Nasdaq: UFPT) reported record 2025 results: net sales $602.8M (+19.5% YoY), net income $68.3M (+15.8% YoY) and GAAP EPS $8.75. Medical sales rose 23.2% to $555.3M while non-medical fell 11.5% to $47.5M. Adjusted EBITDA was $121.1M.
The company noted AJR labor inefficiencies cost ~$6.3M in 2025, easing to $1.2M in Q4, and highlighted facility expansion and contract extensions in the Dominican Republic plus recent acquisitions integrating into operations.
UFP Technologies (Nasdaq: UFPT) will report fourth quarter and year-end 2025 results on February 24, 2026 after market close and host a conference call on February 25, 2026 at 8:30 AM ET.
Investors may join via the provided toll-free numbers or a live webcast; a replay will be available on the company’s Investor Relations website.
UFP Technologies (Nasdaq: UFPT) announced a planned CEO succession: R. Jeffrey Bailly will retire as CEO at the company’s next annual meeting on June 4, 2026. At that time, President Mitchell Rock will become CEO and join the Board, while Bailly will serve as Executive Chairman for one year to facilitate the transition.
The release notes Bailly’s 31-year tenure, company expansion to operations in five countries, a workforce of nearly 5,000 associates, and historical growth of about 20-fold revenue and >150-fold profitability and market capitalization under his leadership.
UFP Technologies (Nasdaq: UFPT) announced that Chairman & CEO R. Jeffrey Bailly, President Mitchell C. Rock, and CFO Ron Lataille will present and host 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference in New York City, December 1-4, 2025.
UFP's presentation is scheduled for 8:10 AM ET on Wednesday, December 3, 2025, and a live audio webcast of the presentation will be available.
UFP Technologies (Nasdaq: UFPT) reported Q3 2025 net income of $16.4M or $2.11 diluted EPS, matching Q3 2024, and adjusted EPS of $2.39. Q3 sales were $154.6M (+6.5% YoY) and nine-month sales were $453.9M (+26.0% YoY). Nine-month net income was $50.7M versus $42.6M year‑ago. Medical market sales strengthened (+31.1% YTD). The company cited $3M incremental labor costs at its Illinois AJR facility and > $8M of unfulfilled Q3 orders tied to that issue. Management highlighted DR facility ramp, robotic surgery program launches, and two recent acquisitions performing ahead of expectations.
UFP Technologies (Nasdaq: UFPT) will report third-quarter 2025 financial results on Monday, November 3, 2025 after market close. A conference call to discuss results is scheduled for Tuesday, November 4, 2025 at 8:30 AM Eastern. Participants can join by the listed toll-free dial-ins for USA/Canada and international numbers, or listen via a live webcast. A replay of the webcast and accompanying materials will be available on the company’s Investor Relations website at https://ufpt.com/investors/.